Results 11 to 20 of about 10,242 (284)
Botulinum toxin type A therapy for blepharospasm [PDF]
Cochrane Database of Systematic Reviews, 2020 This is an update of a Cochrane Review first published in 2005. Blepharospasm is the second most common form of focal dystonia. It is a disabling disorder, characterised by chronic, intermittent or persistent, involuntary eyelid closure, due to spasmodic contractions of the orbicularis oculi muscles.
Duarte, GS +7 more
openaire +5 more sources
Toxins, 2021 Botulinum toxin type A (BoNT-A) represents a first-line treatment for spasticity, a common disabling consequence of many neurological diseases. Electrical stimulation of motor nerve endings has been reported to boost the effect of BoNT-A. To date, a wide
Alessandro Picelli +6 more
doaj +1 more source
rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis
Frontiers in Microbiology, 2022 Botulinum neurotoxin (BoNT) is one of the most dangerous bacterial toxins and a potential biological weapon component. BoNT mechanism of pathological action is based on inhibiting the release of neurotransmitters from nerve endings.
Artem A. Derkaev +9 more
doaj +1 more source
Treating the face of women with botulinum toxin type A: 7-year review [PDF]
Revista Brasileira de Cirurgia Plástica, 2023 Introduction: Botulinum toxin type A (BTX-A) is the number one aesthetic procedure worldwide, and the difficulty in standardizing the aesthetic treatment of the face results in a broad range of treatment possibilities.
Victor Hugo Lara Cardoso Sá +3 more
doaj +1 more source
Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome [PDF]
International Neurourology Journal, 2015 Intravesical onabotulinumtoxinA (BoNT-A) injection is an effective treatment for overactive bladder syndrome (OAB) that is refractory to antimuscarinics.
Chun-Hou Liao, Hann-Chorng Kuo
doaj +1 more source
Botulinum Toxin as Preventive Treatment for Migraine: A Randomized Double-Blind Study [PDF]
, 2009 Aim: To determine if botulinum toxin type A (BoNT-A) injections can reduce the frequency and severity of migraines. Methods: Patients (n = 127) were randomized to receive placebo or two doses of BoNT-A (Dysport (R)). The primary endpoint was reduction in
Toelle, Thomas +11 more
core +1 more source
Brazilian Oral Research, 2018 Botulinum toxin type A is effective in reducing excessive gingival display caused by hyperfunctional upper lip elevator muscles; however, this effect is transient.
Taísa Figueiredo Chagas +5 more
doaj +1 more source
Applied Sciences, 2021 Botulinum toxins or neurotoxins (BoNTs) are the most potent neurotoxins known, and are currently extensively studied, not only for their potential lethality, but also for their possible therapeutic and cosmetic uses.
Massimo Corsalini +10 more
doaj +1 more source
Clinical Case Reports, 2020 The use of preoperative ventral botulinum toxin for giant hiatal hernia management.
Francisco Tustumi +8 more
doaj +1 more source
Toxins, 2023 DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A product containing daxibotulinumtoxinA with a stabilizing excipient peptide (RTP004).
Conor J. Gallagher +6 more
doaj +1 more source